BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Waked I, Shiha G, Qaqish RB, Esmat G, Yosry A, Hassany M, Soliman R, Mohey MA, Allam N, Zayed N, Asselah T, Hall C, Redman R, Mobashery N, Doss W. Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol 2016;1:36-44. [PMID: 28404110 DOI: 10.1016/S2468-1253(16)30002-4] [Cited by in Crossref: 47] [Cited by in F6Publishing: 18] [Article Influence: 7.8] [Reference Citation Analysis]
Number Citing Articles
1 Burstow NJ, Mohamed Z, Gomaa AI, Sonderup MW, Cook NA, Waked I, Spearman CW, Taylor-Robinson SD. Hepatitis C treatment: where are we now? Int J Gen Med 2017;10:39-52. [PMID: 28255252 DOI: 10.2147/IJGM.S127689] [Cited by in F6Publishing: 21] [Reference Citation Analysis]
2 Di Biagio A, Taramasso L, Cenderello G. Treatment of hepatitis C virus genotype 4 in the DAA era. Virol J 2018;15:180. [PMID: 30466446 DOI: 10.1186/s12985-018-1094-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.8] [Reference Citation Analysis]
3 Waked I, Esmat G, Fouad R, Allam N, Hassany M, Mohey M, Shiha G, Soliman R, Qaqish RB, Hall C, Alami NN, Kopecky-Bromberg S, Mobashery N. Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study. J Med Virol 2018;90:1739-44. [PMID: 29900553 DOI: 10.1002/jmv.25243] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
4 Asselah T, Alami NN, Moreno C, Pol S, Karatapanis S, Gschwantler M, Horsmans Y, Elefsiniotis I, Larrey D, Ferrari C, Rizzetto M, Orlandini A, Calleja JL, Bruno S, Schnell G, Qaqish R, Redman R, Pilot-Matias T, Kopecky-Bromberg S, Yu Y, Mobashery N. Ombitasvir/paritaprevir/ritonavir plus ribavirin for 24 weeks in patients with HCV GT4 and compensated cirrhosis (AGATE-I Part II). Health Sci Rep 2019;2:e92. [PMID: 30937389 DOI: 10.1002/hsr2.92] [Reference Citation Analysis]
5 Asselah T, Moreno C, Sarrazin C, Gschwantler M, Foster GR, Craxí A, Buggisch P, Sanai F, Bicer C, Lenz O, Van Dooren G, Nalpas C, Lonjon-Domanec I, Schlag M, Buti M. Efficacy of a 12-Week Simeprevir Plus Peginterferon/Ribavirin (PR) Regimen in Treatment-Naïve Patients with Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection and Mild-To-Moderate Fibrosis Displaying Early On-Treatment Virologic Response. PLoS One 2017;12:e0168713. [PMID: 28056030 DOI: 10.1371/journal.pone.0168713] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
6 Aygen B, Demirtürk N, Yıldız O, Çelen MK, Çelik İ, Barut Ş, Ural O, Batırel A, Mıstık R, Şimşek F, Asan A, Ersöz G, Türker N, Bilgin H, Kınıklı S, Karakeçili F, Zararsız G, Turkish Society Of Clinical Microbiology And Infectious Diseases TSGFVHOT. Real-world efficacy, safety, and clinical outcomes of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin combination therapy in patients with hepatitis C virus genotype 1 or 4 infection: The Turkey experience experience. Turk J Gastroenterol 2020;31:305-17. [PMID: 32412901 DOI: 10.5152/tjg.2020.19197] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Abd Alla MDA, Dawood RM, Rashed HAE, Farrag G, Ammar IAE, Mahmoud MMA, Salum GM, Altanbouly AMA, El Meguid MA, Awady MKE. Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes. Arch Virol 2021;166:1071-81. [PMID: 33533976 DOI: 10.1007/s00705-021-04969-4] [Reference Citation Analysis]
8 Shiha G, Esmat G, Hassany M, Soliman R, Elbasiony M, Fouad R, Elsharkawy A, Hammad R, Abdel-Razek W, Zakareya T, Kersey K, Massetto B, Osinusi A, Lu S, Brainard DM, McHutchison JG, Waked I, Doss W. Ledipasvir/sofosbuvir with or without ribavirin for 8 or 12 weeks for the treatment of HCV genotype 4 infection: results from a randomised phase III study in Egypt. Gut 2019;68:721-8. [PMID: 29666174 DOI: 10.1136/gutjnl-2017-315906] [Cited by in Crossref: 21] [Cited by in F6Publishing: 19] [Article Influence: 5.3] [Reference Citation Analysis]
9 Bourlière M, Pietri O, Castellani P, Oules V, Adhoute X. Sofosbuvir, velpatasvir and voxilaprevir: a new triple combination for hepatitis C virus treatment. One pill fits all? Is it the end of the road? Therap Adv Gastroenterol 2018;11:1756284818812358. [PMID: 30574189 DOI: 10.1177/1756284818812358] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
10 Keating GM. Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection. Drugs. 2016;76:1203-1211. [PMID: 27401997 DOI: 10.1007/s40265-016-0612-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 2.2] [Reference Citation Analysis]
11 Abdallah FM, Helmy MW, Katary MA, Ghoneim AI. Synergistic antiproliferative effects of curcumin and celecoxib in hepatocellular carcinoma HepG2 cells. Naunyn Schmiedebergs Arch Pharmacol. 2018;391:1399-1410. [PMID: 30155693 DOI: 10.1007/s00210-018-1557-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 4.5] [Reference Citation Analysis]
12 Shiha G, Soliman R, ElBasiony M, Hassan AA, Mikhail NNH. Sofosbuvir plus Daclatasvir with or without ribavirin for treatment of chronic HCV genotype 4 patients: real-life experience. Hepatol Int 2018;12:339-47. [PMID: 29663115 DOI: 10.1007/s12072-018-9861-2] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
13 Gschwantler M, Bamberger T, Graziadei I, Maieron A, Katalinic N, Stauber R. Burden of disease in patients with chronic hepatitis C in the Austrian REAL study. Wien Klin Wochenschr 2019;131:8-16. [PMID: 30430232 DOI: 10.1007/s00508-018-1404-2] [Reference Citation Analysis]
14 Ferreira VL, Tonin FS, Assis Jarek NA, Ramires Y, Pontarolo R. Efficacy of Interferon-Free Therapies for Chronic Hepatitis C: A Systematic Review of All Randomized Clinical Trials. Clin Drug Investig 2017;37:635-46. [PMID: 28409482 DOI: 10.1007/s40261-017-0521-4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
15 El Kassas M, El Sheemy R, Alboraie M, El Badry M, Wifi MN, Youssef N, Ezzat S, Tahoon M, Abdelsalam L, Abdelhakam SM, Ali-Eldin Z. Real-world results of direct-acting antivirals use for the treatment of chronic hepatitis C in old patients. Eur Geriatr Med 2019;10:295-302. [PMID: 34652758 DOI: 10.1007/s41999-019-00167-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
16 Jones CR, Flower BF, Barber E, Simmons B, Cooke GS. Treatment optimisation for hepatitis C in the era of combination direct-acting antiviral therapy: a systematic review and meta-analysis. Wellcome Open Res 2019;4:132. [PMID: 31754636 DOI: 10.12688/wellcomeopenres.15411.1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 3.7] [Reference Citation Analysis]
17 Shiha G, Soliman R, Elbasiony M, Darwish NHE, Mousa SA. Novel combined single dose anti-hepatitis C therapy: a pilot study. Sci Rep 2021;11:4623. [PMID: 33633233 DOI: 10.1038/s41598-021-84066-3] [Reference Citation Analysis]
18 Ferenci P, Bourgeois S, Buggisch P, Norris S, Curescu M, Larrey D, Marra F, Kleine H, Dorr P, Charafeddine M, Crown E, Bondin M, Back D, Flisiak R. Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries. J Viral Hepat 2019;26:685-96. [PMID: 30739368 DOI: 10.1111/jvh.13080] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
19 El-Hamamsy M, Montasser IF, Mansy AE, Nabet DE, El-Meteini M. Effect of cyclosporine A versus tacrolimus on the response to antiviral therapy after hepatitis C genotype-4 recurrence post-liver transplantation: A prospective cohort trial. J Clin Pharm Ther 2019;44:447-53. [PMID: 30714175 DOI: 10.1111/jcpt.12807] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
20 Shiha G, Soliman R, Elbasiony M, Darwish NHE, Mousa SA. Addition of Epigallocatechin Gallate 400 mg to Sofosbuvir 400 mg + Daclatisvir 60 mg With or Without Ribavirin in Treatment of Patients with Chronic Hepatitis C Improves the Safety Profile: A Pilot Study. Sci Rep 2019;9:13593. [PMID: 31537880 DOI: 10.1038/s41598-019-49973-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]